Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 176 participants.

Also called NCT03262363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 176 participants (planned count) (from the registry)
Sponsor
Unidad de Investigacion Medica en Enfermedades Renales (from the registry)
Registry
  • NCT NCT03262363
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03262363. Randomized; triple masking; primary purpose treatment. Start 2018-08-01 (anticipated); primary completion 2019-02-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy
Acronym
CURCUNRF2
Condition
Chronic Kidney Diseases
Condition
Diabetes Mellitus, Type 2
Condition
Polymorphism
Intervention (Combination product)
Curcumin/NFE2L2 A>G
Intervention (Combination product)
Placebo/NFE2L2 A>G
Lead sponsor
Unidad de Investigacion Medica en Enfermedades Renales (class: other)

Record details

Record id
cardio:ct-nct03262363
Content hash
06972236deea088c84e9b8b4163312f49e3417946573440d9fb9650e76cef934